References
- Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. The Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
- Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
- Mellstrom D, Sorenson OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
- Hannon R, Purple C, Klemes A, et al. Offset of action on bone resorption after 7 years of risedronate therapy. Bone 2009;44:S238
- Eastell R, Hannon R, Wenderoth D. Re-initiation of risedronate 5 mg daily therapy in patients on long-term treatment after 1 year of discontinuation: effects at 9 and 10 years. Bone 2010;46:S23-4
- Canadian Food and Drug Regulations C.R.C., c.870, C.08.002.1
- Canadian Food and Drug Regulations C.R.C., c.870, C.08.001.1
- Health Canada Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies – Part A: Oral Dosage Formulations Used for Systemic Effects. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/bio-a-eng.pdf [Last accessed 19 July 2011]
- Lanza FL, Hunt RH, Thomson ABR, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631-8
- Thomson ABR, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by helicobacter pylori status. J Rheumatol 2002;29:1965-74
- Miller RG, Bolognese M, Worley K, et al. Incidence of gastrointestinal events among bisphosphonates patients in an observational setting. Am J Manag Care 2004;10:S207-16
- Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997;92:1322-5
- Perkins AC, Wilson CG, Frier M, et al. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int J Pharm 1999;186:169-75
- Perkins AC, Wilson CG, Frier M, et al. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. Int J Pharmaceuticals 2001;222:295-303
- de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of aldendronate. N Engl J Med 1996;335:1016-21
- Health Canada Alendronate-induced esophagitis Canadian Adverse Drug Reaction Newsletter April 1998;8(2):1-4 also available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/carn-bcei_v8n2-eng.pdf [Last accessed 19 July 2011]
- Merck Frosst Canada & Co. Fosamax Product Monograph. Kirkland Quebec, March 20, 2000
- Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008;24:1137-45
- Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Curr Med Res Opin 2009;25:449-52
- Olszynski WP, Adachi JD. Disintegration times of brand and generic bisphosphonates available in Canada. J Bone Miner Res 2010;25:S125
- Grima DT, Papaioannou A, Airia P, et al. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 2010;11:68
- Ringe JD, Möller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;30:213-21
- United States Pharmacopeial Convention. 2010 United States Pharmacopeia National Formulary 33rd Edition. United States Pharmacopeial Convention Inc.: Rockville, MD, 2010
- AusPAR Alendracord, Alendrocor and Pharmacor Alendronate Alendronic acid Accord Healtcare Pty Ltd PM-2009-01135-3-5 Final 16 February 2011
- Apotex Inc. Apo-Risedronate Product Monograph. Toronto ON, July 22, 2010
- Pharmascience Inc. pms-Risedronate Product Monograph. Montreal QU, May 31, 2010
- Laboratoire Riva Inc. Riva-risedronate Product Monograph. Blainville QU, July 23, 2010
- Pro Doc Ltée Risedronte Product Monograph. Laval QU, March 24, 2010
- Shakweh M, Bravo-Osuna I, Ponchel G. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharmaceut Sci 2007;31:262-70